Assessing the role of adolescent hormonal contraceptive use on risk for depression: a 3-year longitudinal study protocol
department or school: Arts, Faculty of
department or school: Medicine, Faculty of
department or school: Pharmaceutical Sciences, Faculty of
department or school: Non UBC
department or school: Medicine, Department of
department or school: Population and Public Health (SPPH), School of
data provider: DSpace
identifier citation: BMC Women's Health. 2022 Feb 23;22(1):48
contributor: Djavad Mowafaghian Centre for Brain Health
contributor: Centre for Menstrual Cycle and Ovulation Research
contributor: Women's Health Research Institute (British Columbia)
contributor: Children's Hospital (Vancouver, B.C.). Research Institute
rights copyright: The Author(s)
creator: Zareian, Bita
creator: Anderl, Christine
creator: LeMoult, Joelle
creator: Galea, Liisa A. M.
creator: Prior, Jerilynn C., 1943-
creator: Rights, Jason D.
creator: Ross, Colin J.
creator: Ge, Sabrina
creator: Hayward, Annie C.
creator: Chen, Frances S.
issued: 2022-03-30T17:38:11Z
issued: 2022-02-23
description: Background The incidence of depression in human females rises steadily throughout adolescence, a critical period of pubertal maturation marked by increasing levels of gonadal hormones including estrogens and progesterone. These gonadal hormones play a central role in social and emotional development and may also contribute to the increased occurrence of depression in females that begins in early adolescence. In this study, we examine whether and how introducing synthetic estrogen and progestin derivatives through the use of combined hormonal contraceptives (CHC), affects adolescent females’ risk for developing depression. We further assess potential links between CHC use and alterations in stress responses and social-emotional functioning. Methods Using a longitudinal cohort design, we will follow a sample of adolescent females over the span of three years. Participants will be assessed at three time points: once when they are between 13 and 15 years of age, and at approximately 18 and 36 months after their initial assessment. Each time point will consist of two online sessions during which participants will complete a clinical interview that screens for key symptoms of mental health disorders, along with a series of questionnaires assessing their level of depressive symptoms and history of contraceptive use. They will also complete a standardized social-evaluative stress test and an emotion recognition task, as well as provide saliva samples to allow for assessment of their circulating free cortisol levels. Discussion In this study we will assess the effect of CHC use during adolescence on development of Major Depressive Disorder (MDD). We will control for variables previously found to or proposed to partially account for the observed relationship between CHC use and MDD, including socioeconomic status, age of sexual debut, and CHC-related variables including age of first use, reasons for use, and its duration. In particular, we will discover whether CHC use increa…
aggregated CHO: https://circle.library.ubc.ca/rest/handle/2429/81055
note: Zareian et al. BMC Women’s Health (2022) 22:48 https://doi.org/10.1186/s12905-022-01623-2STUDY PROTOCOLAssessing the role of adolescent hormonal contraceptive use on risk for depression: a 3-year longitudinal study protocolBita Zareian1†, Christine Anderl1,2†, Joelle LeMoult1, Liisa A. M. Galea1,3, Jerilynn C. Prior4,5,6,9 , Jason D. Rights1, Colin J. Ross7,8, Sabrina Ge1, Annie C. Hayward1 and Frances S. Chen1* Abstract Background: The incidence of depression in human females rises steadily throughout adolescence, a critical period of pubertal maturation marked by increasing levels of gonadal hormones including estrogens and progesterone. These gonadal hormones play a central role in social and emotional development and may also contribute to the increased occurrence of depression in females that begins in early adolescence. In this study, we examine whether and how introducing synthetic estrogen and progestin derivatives through the use of combined hormonal contra-ceptives (CHC), affects adolescent females’ risk for developing depression. We further assess potential links between CHC use and alterations in stress responses and social-emotional functioning.Methods: Using a longitudinal cohort design, we will follow a sample of adolescent females over the span of three years. Participants will be assessed at three time points: once when they are between 13 and 15 years of age, and at approximately 18 and 36 months after their initial assessment. Each time point will consist of two online sessions during which participants will complete a clinical interview that screens for key symptoms of mental health disorders, along with a series of questionnaires assessing their level of depressive symptoms and history of contraceptive use. They will also complete a standardized social-evaluative stress test and an emotion recognition task, as well as provide saliva samples to allow for assessment of their circulating free cortisol levels.Discussion: In this study we will assess…
has type: Article
is shown at: 10.14288/1.0407448
language: eng
peer review status: Reviewed
provider: Vancouver : University of British Columbia Library
publisher: BioMed Central
publisher DOI: 10.1186/s12905-022-01623-2
rights: Attribution 4.0 International (CC BY 4.0)
rights URI: http://creativecommons.org/licenses/by/4.0/
scholar level: Faculty
scholar level: Researcher
subject: Birth control
subject: Stress reactivity
subject: Cortisol
subject: Puberty
subject: Emotional development
subject: Social functioning
subject: Major depressive disorder
subject: Mood disorder
subject: Mental health
type: Text
identifier URI: http://hdl.handle.net/2429/81055